Literature DB >> 2153173

Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules.

G F Fischer1, O Majdic, S Gadd, W Knapp.   

Abstract

The CD24 Ag is present on human B cells from the earliest stages of B lineage development and is lost on terminal B cell maturation to plasma cells. This Ag is also expressed on mature forms of granulocytes. We studied the effects of CD24 mAb on the function of both lymphocytic and myeloid cell types. We found a clear-cut increase in free cytoplasmic calcium when tonsil B cells or mononuclear cells from B cell chronic lymphatic leukemia patients were preincubated with CD24 mAb and further stimulated with goat F(ab')2 anti-mouse Ig antibodies. The same experimental setting with granulocytes instead of B lymphocytes led to the triggering of hydrogen peroxide production in these cells. CD24 Ag is expressed at higher levels on activated granulocytes and is anchored to the plasma membrane by a phosphoinositol linkage. In conclusion we provide evidence that the CD24 Ag are functional molecules in cells of different lineage, playing a signal transducing role in cell function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153173

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  CD antigens as promising tools for the functional analysis of solid tumours.

Authors:  P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis.

Authors:  T Felzmann; S Gadd; O Majdic; D Maurer; P Petera; J Smolen; W Knapp
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

3.  The Role of PEC Progenitors in ADPKD Progression.

Authors:  Daniele Lodi; Giulia Ligabue; Valentina Lupo; Fabrizio Cavazzini
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

Review 4.  Cancer stem cells as a potential therapeutic target in breast cancer.

Authors:  Mingzhi Zhang; Zhaoming Li; Xudong Zhang; Yu Chang
Journal:  Stem Cell Investig       Date:  2014-07-16

5.  Induction of neutrophil homotypic adhesion via sialophorin (CD43), a surface sialoglycoprotein restricted to haemopoietic cells.

Authors:  A R Rosenkranz; O Majdic; J Stöckl; W Pickl; H Stockinger; W Knapp
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

6.  Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.

Authors:  Emma Sandén; Cecilia Dyberg; Cecilia Krona; Edward Visse; Helena Carén; Paul A Northcott; Marcel Kool; Nils Ståhl; Annette Persson; Elisabet Englund; John I Johnsen; Peter Siesjö; Anna Darabi
Journal:  J Neurooncol       Date:  2015-03-29       Impact factor: 4.130

7.  Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.

Authors:  E Weber; H P Lehmann; A G Beck-Sickinger; E J Wawrzynczak; R Waibel; G Folkers; R A Stahel
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  Signal transduction via Fc gamma R and Mac-1 alpha-chain in monocytes and polymorphonuclear leucocytes.

Authors:  S J Gadd; R Eher; O Majdic; W Knapp
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

9.  Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

Authors:  Maria Rehnberg; Sylvie Amu; Andrej Tarkowski; Maria I Bokarewa; Mikael Brisslert
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

10.  Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

Authors:  Matthew J Meyer; Jodie M Fleming; Mustapha A Ali; Mitchell W Pesesky; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Breast Cancer Res       Date:  2009-11-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.